EUVIMEDEUVIMED entdecken
Crossref

Osteoporosis and Risk of Hearing Loss: Protective Effects of Zoledronic Acid and Denosumab in a Nationwide Cohort

Shih-Han Hung, Chun-Feng Huang, Jason C Hsu, John J Carey, James F Griffith, Wing P Chan iD

Journal of the American Geriatrics Society · 2026-10 · 74 (10) · 2989-2996

DOI: 10.1111/jgs.70654 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Geriatrics Society, online erschienen am 10.08.2026. Verfasst von Shih-Han Hung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Osteoporosis, Denosumab, Bone Density Conservation Agents, Zoledronic Acid. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Osteoporosis and fragility fractures may be associated with hearing loss, but whether osteoporosis treatments influence this risk remains unclear.

Design

Retrospective cohort study.

Setting

Taiwan's National Health Insurance Research Database (2011–2017).

Participants

For Objective 1, adults aged 65 years and older with osteoporosis or fragility fractures ( n = 331,867) and matched controls ( n = 331,867); for Objective 2, patients with osteoporosis or fragility fractures treated with zoledronic acid ( n = 21,811), treated with denosumab ( n = 21,811), or without treatment ( n = 21,811).

Measurements

The primary outcome was incident hearing loss. Propensity score matching (1:1 or 1:1:1) was performed using age, sex, and Charlson Comorbidity Index covariates. Hazard ratios (HRs) were estimated using Cox proportional hazards models adjusted for comorbidities.

Results

Patients with osteoporosis or fragility fractures showed a significantly higher incidence of hearing loss than controls (adjusted HR: 1.34, 95% CI: 1.31–1.37, p < 0.001). Among affected individuals, those treated with zoledronic acid (HR: 0.87, 95% CI: 0.81–0.93) or denosumab (HR: 0.91, 95% CI: 0.85–0.97) had a significantly lower risk of hearing loss than untreated patients. Zoledronic acid reduced the risk of hearing loss in both sexes, whereas the association of denosumab with reduced risk was statistically significant only in male patients.

Conclusion

Osteoporosis and fragility fractures are associated with an increased risk of hearing loss. Treatment with zoledronic acid was associated with a reduced risk of hearing loss in both sexes, whereas denosumab was associated with such a reduction only in male patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisDenosumabBone Density Conservation AgentsZoledronic AcidHearing LossOsteoporotic FracturesHumansFemaleMaleAgedRetrospective StudiesTaiwanAged, 80 and overIncidenceProportional Hazards ModelsRisk Factors

Stichwörter der Autor:innen

denosumabfragility fracturehearing lossolder adultsosteoporosiszoledronic acid

Substanzen

DenosumabBone Density Conservation AgentsZoledronic Acid

Autor:innen und Institutionen

  • Department of Otolaryngology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Department of Otolaryngology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
  • School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.
  • Department of Family Medicine, Chi Mei Medical Center, Tainan, Taiwan.
  • Department of Leisure Services Management, Chaoyang University of Technology, Taichung, Taiwan.
  • International PhD Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Wing P Chan

Zitieren

APA

Hung, S. H., Huang, C. F., Hsu, J. C., Carey, J. J., Griffith, J. F., & Chan, W. P. (2026). Osteoporosis and Risk of Hearing Loss: Protective Effects of Zoledronic Acid and Denosumab in a Nationwide Cohort. Journal of the American Geriatrics Society, 74(10), 2989-2996. https://doi.org/10.1111/jgs.70654

Vancouver

Hung SH, Huang CF, Hsu JC, Carey JJ, Griffith JF, Chan WP. Osteoporosis and Risk of Hearing Loss: Protective Effects of Zoledronic Acid and Denosumab in a Nationwide Cohort. Journal of the American Geriatrics Society. 2026;74(10):2989-2996. doi:10.1111/jgs.70654

BibTeX
@article{Hung2026,
  author = {Hung, Shih-Han and Huang, Chun-Feng and Hsu, Jason C and Carey, John J and Griffith, James F and Chan, Wing P},
  title = {Osteoporosis and Risk of Hearing Loss: Protective Effects of Zoledronic Acid and Denosumab in a Nationwide Cohort},
  journal = {Journal of the American Geriatrics Society},
  year = {2026},
  volume = {74},
  number = {10},
  pages = {2989--2996},
  doi = {10.1111/jgs.70654}
}
Kostenlos starten →